Systemic antitumor clinical response observed with single or dual immunization schedule. (A) Patient 2 (64-year-old man, stage IIB) was treated with the single immunization procedure. Systemic evaluation site was the left calf, and the immunization site was the left thigh. PR was noted at week 8, with DOR of 12 weeks. Patient met progression criteria per mSWAT score at week 20 and withdrew from the trial to start topical steroid therapy. (B) Patient 9 (71-year-old man, stage IB) received dual immunization treatment. Systemic evaluation sites were the lower legs, and lesions on each thigh served as the immunization sites. PR was noted at week 12, with DOR of 6 weeks. Patient withdrew from trial at week 18 to initiate topical nitrogen mustard to small areas of recurrent skin disease.